Skip to main content
SpringerLink
Log in

Ombitasvir/paritaprevir/ritonavir

Fatal liver failure, hepatic encephalopathy and variceal bleeding: 3 case reports

  • Case report
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Perello C, et al. Effectiveness and safety of ombitasvir, paritaprevir, ritonavir +/- dasabuvir +/- ribavirin: An early access programme for Spanish patients with genotype 1/4 chronic hepatitis C virus infection. Journal of Viral Hepatitis 24: 226-237, No. 3, Mar 2017. Available from: URL: http://doi.org/10.1111/jvh.12637 - Spain

    Article  CAS  PubMed  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ombitasvir/paritaprevir/ritonavir. Reactions Weekly 1695, 288 (2018). https://doi.org/10.1007/s40278-018-44115-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-018-44115-1

Search

Navigation